Suchergebnisse - "Broeders, Nilufer"

PubPharm (46)

1

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

enthalten in: Kidney international reports | 2021

von Barbour, T. | Scully, M. | Ariceta, G. | +54

2

Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296

enthalten in: Kidney international | 2021

von Rondeau, E. | Scully, M. | Ariceta, G. | +61

ErratumFor: Kidney Int. 2020 Jun;97(6):1287-1296. - PMID 32299680

3

5-Year outcomes of the prospective and randomized CISTCERT study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients

enthalten in: Transplant international : official journal of the European Society for Organ Transplantation | 2021

von Pipeleers, L. | Abramowicz, D. | Broeders, N. | +8

4

5‐Year outcomes of the prospective and randomized CISTCERT study comparing steroid withdrawal to replacement of cyclosporine with everolimus in de novo kidney transplant patients

enthalten in: Transplant international | 2021

von Pipeleers, L. | Abramowicz, D. | Broeders, N. | +8

5

Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296

enthalten in: Kidney international | 2020

von Rondeau, E. | Scully, M. | Ariceta, G. | +59

ErratumFor: Kidney Int. 2020 Jun;97(6):1287-1296. - PMID 32299680

6

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

enthalten in: Kidney international | 2020

von Rondeau, E. | Scully, M. | Ariceta, G. | +59

ErratumIn: Kidney Int. 2020 Dec;98(6):1621. - PMID 33276869

7

Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients : a survey of current practice in Europe

enthalten in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | 2018

von Coussement, J. | Maggiore, U. | Manuel, O. | +108

8

Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients : 5-Year Results

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Dantal, J. | Morelon, E. | Rostaing, L. | +17

9

Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation

enthalten in: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons | 2018

von Wissing, K. | Abramowicz, D. | Weekers, L. | +6

10

Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome

enthalten in: Acta clinica Belgica | 2018

von Claes, K. | Massart, A. | Collard, L. | +20

1
2
3
4
5
Nächster »
[5]